Price History
Feb 9, 2026 — Mar 26, 2026Investment Snapshot
- Piotroski F-Score 2/9 — signs of financial weakness
- Loss-making — negative ROE of -5,653.1%
- Revenue declining 42% annually
Clene Inc. - Common Stock (CLNN) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $65 million . Key value metrics: Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Clene Inc. - Common Stock — Fundamental Analysis Summary
On financial health, CLNN shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and negative return on equity of -5,653.1% (sector average: -19.8%).
StockPik's composite Value Score for CLNN is 37/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CLNN reports a high gross margin of 81.9% (sector average: 33.5%) and a negative operating margin of -11,144.3%.
CLNN shows revenue declining at 42% year-over-year, with earnings growing at 34%.